These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38318236)

  • 21. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
    J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
    Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control.
    Konno S; Uchi T; Kihara H; Sugimoto H
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
    Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
    Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
    Sivadasan A; Bril V
    Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
    Habib AA; Benatar M; Vu T; Meisel A; Attarian S; Katsuno M; Liao S; Beasley KN; Howard JF
    Eur J Neurol; 2024 Oct; ():e16490. PubMed ID: 39373062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World experience with efgartigimod in patients with myasthenia gravis.
    Fuchs L; Shelly S; Vigiser I; Kolb H; Regev K; Schwartzmann Y; Vaknin-Dembinsky A; Dori A; Karni A
    J Neurol; 2024 Jun; 271(6):3462-3470. PubMed ID: 38528163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
    Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
    Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exacerbation of Thymoma-Associated Myasthenia Gravis Following Efgartigimod Treatment Related to Anti-acetylcholine Receptor Antibody Overshoot: A Report of Two Cases.
    Kawama K; Warabi Y; Bokuda K; Kimura H; Takahashi K
    Cureus; 2023 Dec; 15(12):e50692. PubMed ID: 38229781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
    Guptill JT; Sleasman JW; Steeland S; Sips M; Gelinas D; de Haard H; Azar A; Winthrop KL
    Autoimmunity; 2022 Dec; 55(8):620-631. PubMed ID: 36036539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
    Li J; Wu X; Chu T; Tan X; Wang S; Qu R; Chen Z; Wang Z
    J Neurol; 2024 May; 271(5):2298-2308. PubMed ID: 38431900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan.
    Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Ishizuchi K; Tokuyasu D; Handa H; Yasuda M; Kawaguchi N; Kimura T; Suzuki Y; Sugimoto T; Minami N; Takahashi MP; Murai H; Utsugisawa K
    Neurol Clin Pract; 2024 Jun; 14(3):e200276. PubMed ID: 38544885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
    Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
    Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
    Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.
    Horiuchi K; Nakamura S; Yamada K; Inoue T; Oiwa K
    Neuromuscul Disord; 2024 Jun; 39():37-41. PubMed ID: 38772072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
    Wang L; Wang S; Yang H; Han J; Zhao X; Han S; Zhang Y; Lv J; Zhang J; Li M; Ji Y; Zhou S; He X; Fang H; Yang J; Zhang Y; Zhang Q; Gao P; Gao F
    Brain Behav; 2021 Jul; 11(7):e02203. PubMed ID: 34075720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.
    Frangiamore R; Rinaldi E; Vanoli F; Andreetta F; Ciusani E; Bonanno S; Maggi L; Gallone A; Colasuonno A; Tramacere I; Cheli M; Pinna A; Mantegazza R; Antozzi C
    Eur J Neurol; 2024 Apr; 31(4):e16189. PubMed ID: 38164996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.